Canakinumab effective in treating systemic juvenile idiopathic arthritis
How to Cite
OrthoEvidence. Canakinumab effective in treating systemic juvenile idiopathic arthritis. ACE Report. 2013;2(4):163. Available from: https://myorthoevidence.com/AceReport/Report/4367
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisN Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
177 patients, suffering from systemic juvenile idiopathic arthritis (JIA) with active systemic features, who had been chosen to participate in two trials between July 2009 and December 2010, were randomised into two groups to either receive canakinumab or a placebo. Patients in Trial 1 received either canakinumab or the placebo for 29 days. Trial 2 incorporated a two-part withdrawal design, which ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE